CSBR
Champions Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.16
−2.27%Year over year
Reported trailing growth
- Revenue
- +4.4%
- EBITDA
- -92.9%
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -15.5%
- EBITDA
- +556.1%
- EPS
- +237.5%
Three-year CAGR
- Revenue
- +3.3%
- EBITDA
- -92.9%
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Apr 1, 2026